ID   Calu3-GemR
AC   CVCL_EQ19
DR   cancercelllines; CVCL_EQ19
DR   GEO; GSM159359
DR   GEO; GSM159360
DR   GEO; GSM159361
DR   GEO; GSM159362
DR   GEO; GSM159363
DR   GEO; GSM159364
DR   GEO; GSM159365
DR   GEO; GSM159366
DR   GEO; GSM159367
DR   GEO; GSM159368
DR   GEO; GSM159369
DR   GEO; GSM159370
DR   GEO; GSM159371
DR   GEO; GSM159372
DR   GEO; GSM159373
DR   GEO; GSM159374
DR   Wikidata; Q54808428
RX   PubMed=17483357;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0609 ! Calu-3
SX   Male
AG   25Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 9
//
RX   PubMed=17483357; DOI=10.1158/0008-5472.CAN-06-4495;
RA   Tooker P., Yen W.-C., Ng S.-C., Negro-Vilar A., Hermann T.W.;
RT   "Bexarotene (LGD1069, Targretin), a selective retinoid X receptor
RT   agonist, prevents and reverses gemcitabine resistance in NSCLC cells
RT   by modulating gene amplification.";
RL   Cancer Res. 67:4425-4433(2007).
//